Physiomics Secures New Contract in ADC Oncology Sector

The latest update is out from Physiomics ( (GB:PYC) ).

Physiomics plc has secured a new contract with a UK-based biotech company focused on antibody drug conjugates (ADCs) for treating difficult cancers. This project, valued at £102,000, involves developing a Pharmacokinetic (PK) Pharmacodynamic (PD) model to optimize dosing for the client’s upcoming First-in-Human trial, running from April to August 2025. The contract reflects Physiomics’ strategy to diversify its client base and expand into new therapeutic areas, enhancing its industry positioning in the oncology treatment sector.

More about Physiomics

Physiomics plc is a leading company in the field of mathematical modelling, data science, and biostatistics, specializing in the development of new therapeutics and personalized medicine solutions. The company combines expertise in Modelling & Simulation, Biostatistics, Data Science, and Bioinformatics to assist biotech and pharma companies in optimizing their drug development processes. Physiomics has contributed to over 100 commercial projects, working with clients such as Merck KGaA, Astellas, and Bicycle Therapeutics.

YTD Price Performance: -42.00%

Average Trading Volume: 5,073,715

Technical Sentiment Consensus Rating: Buy

Current Market Cap: £1.32M

For an in-depth examination of PYC stock, go to TipRanks’ Stock Analysis page.